Vaccines against nicotine: How effective are they likely to be in preventing smoking?

CNS Drugs

Volumn 15, Issue 7, 2001, Pages 505-514

  Vocci, F J ^a   Chiang, C N ^a  

^a Division of Treatment Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE; NICOTINE VACCINE; UNCLASSIFIED DRUG; VACCINE;

BRAIN; CAUSE OF DEATH; CHILD BEHAVIOR; CHRONIC DISEASE; CIGARETTE SMOKING; DYING; HEALTH PROGRAM; HEALTH PROMOTION; IMMUNOGENICITY; INDUSTRIALIZATION; MORTALITY; PRIORITY JOURNAL; PUBLIC HEALTH; RELAPSE; REVIEW; SMOKING CESSATION;

EID: 0034904631     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200115070-00001     Document Type: Review

References (61)

1. Mortality from tobacco in developed countries: Indirect estimation from national vital statistics
2. The health consequences of smoking
3. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats
4. Depression of mesolimbic dopamine transmission and sensitization to morphine during opiate abstinence
5. Persistent behavior at high rates maintained by intravenous nicotine administration
6. Nicotine as a reinforcer in human subjects and laboratory animals
7. Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine
8. Nicotine delivery kinetics and abuse liability
9. Pharmacological aspects of cigarette smoking and nicotine addiction
10. Transdermal nicotine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation
11. Fixed-interval schedule of cocaine reinforcement: Effect of dose and infusion duration
12. The rate hypothesis and agonist substitution approaches to cocaine abuse treatment
13. Priming effects with drugs and other reinforcers
14. Experimental model of smoking re-exposure: Effects on relapse
15. Brain monoamine oxidase A inhibition in cigarette smokers
16. Neuropharmacological actions of cigarette smoke: Brain monoamine oxidase B (MAO B) inhibition
17. Non-nicotine pharmacotherapy for smoking cessation
18. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
19. Advances in non-nicotine pharmacotherapy for smoking cessation
20. Unconventional vaccine targets: Immunization for pregnancy, peptic ulcer, gastric cancer, cocaine abuse, and atherosclerosis
21. Changes in heroin self-administration by a rhesus monkey after morphine immunization
22. A potential vaccine for cocaine abuse prophylaxis
23. Suppression of psychoactive effects of cocaine by active immunization
24. Active immunization with cocaine-protein conjugate attenuates cocaine effects
25. Efficacy of a therapeutic cocaine vaccine in rodent models
26. Development of a therapeutic vaccine for the treatment of cocaine addiction
27. Evaluation of anticocaine antibodies and cocaine vaccine in a rat self-administration model
28. Active immunization alters the plasma nicotine concentration in rats
29. Immunization of rats reduces nicotine distribution to brain
30. A nicotine conjugate vaccine reduces nicotine distribution to brain and accentuates its behavioral and cardiovascular effects in rats
31. Recent advances in vaccine adjuvants for systemic and mucosal administration
32. Adjuvants and delivery systems for viral vaccines: Mechanisms and potential
33. Clinical pharmacology of nicotine
34. Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: Implication for addiction
35. Neuropharmacological effects of nicotine in relation to cholinergic mechanisms
36. Higher levels of nicotine in arterial than in venous blood after cigarette smoking
37. Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine
38. Humoral recall responses in HIV infection: Levels, specificity, and affinity of antigen-specific IgG
39. Response of recent human immunodeficiency virus seroconverters to the pneumococcal polysaccharide vaccine and Haemophilus influenzae type b conjugate vaccine
40. Pharmacodynamics of a monoclonal antiphencyclidine Fab with broad selectivity for phencyclidine-like drugs
41. Daily intake of nicotine during cigarette smoking
42. How the steady-state cotinine concentration in cigarette smokers is directly related to nicotine intake
43. The pharmacology of cocaine smoking in humans
44. Vaccination against nicotine during continued nicotine administration in rats: Immunogenicity of the vaccine and effects on nicotine distribution to brain
45. Effects of passive immunization against morphine on heroin self-administration
46. Smokers of low-yield cigarettes do not consume less nicotine
47. Specific antibodies and Fab fragments to alter the pharmacokinetics and reverse the pharmacologic/toxicologic effects of drugs
48. Antiphencyclidine monoclonal antibody therapy significantly change phencyclidine concentration in brain and other tissues in rats
49. Altered disposition of repeated nicotine doses in rats immunized against nicotine
50. Circadian blood nicotine concentrations during cigarette smoking
51. Human cocaine vaccine: Safety and immunogenicity
52. Cigarette smoking among adults: United States 1997
53. Cigarette smoking among adults: United States 1995
54. Has smoking cessation ceased? Expected trends in the prevalence of smoking in the United States
55. Epidemiology of tobacco use and dependence
56. Teenage smoking, attempts to quit, and school performance
57. Nicotine patch therapy in 101 adolescent smokers
58. Trends in cigarette smoking in the United States: Projections to the year 2000